The U.S. cell and gene therapy clinical trials market has entered a phase of accelerated expansion, reflecting both national leadership in biotechnology and global interconnectivity in clinical research. Valued at USD 5.36 billion in 2024, the market is projected to expand at a CAGR of 15.3% from 2025 to 2034, underscoring the rapid integration of innovative therapeutic platforms across research and healthcare ecosystems. While the U.S. remains the epicenter of trial activity due to robust funding pipelines, specialized infrastructure, and strong Food and Drug Administration (FDA) oversight, international linkages with Eur
Respect!
Kommentar
Delen
